Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

  • Technology appraisal guidance
  • TA305
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence:

  • Shyangdan DS, Cummins E, Clar C et al. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion – a single technology assessment. October 2013

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups gave their expert views on aflibercept solution for injection for the treatment of macular oedema caused by central retinal vein occlusion by providing a written statement to the Committee. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Bayer

Professional or specialist and patient or carer groups:

  • Macular Society

  • Organisation of Blind African Caribbeans

  • Royal College of Nursing

  • Royal College of Ophthalmologists

  • Royal College of Pathologists

  • Royal National Institute of Blind People (RNIB)

  • South Asian Health Foundation

Other consultees:

  • Department of Health

  • NHS Coventry and Rugby Clinical Commissioning Group

  • NHS Enfield Clinical Commissioning Group

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Allergan

  • Cochrane Eyes and Vision Group

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • National Institute for Health Research Health Technology Assessment Programme

  • Novartis Pharmaceuticals

  • Roche Products

  • Warwick Evidence

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on aflibercept solution for injection for the treatment of macular oedema caused by central retinal vein occlusion by providing oral evidence to the Committee.

  • Ian Pearce, Consultant Ophthalmologist, nominated by Bayer – clinical specialist

  • Sobha Sivaprasad, Consultant Ophthalmologist, nominated by Royal College of Ophthalmologists – clinical specialist

  • Cathy Yelf, Head External Relations, nominated by Macular Society – patient expert

  • Clara Eaglen, Policy and Campaigns Manager, nominated by RNIB – patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bayer

ISBN 978-1-4731-0446-4